GlassScriptPhysician profile
Andreh Carapiet
NPI 1649520909
$1,348.56
in general payments reported to CMS, 2019-2025
15 companies · $95.10 in 2025
The $95.10 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $58.82 · 2020: $94.36 · 2021: $203 · 2022: $207 · 2023: $337 · 2024: $354 · 2025: $95.10.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $785.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $785.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $345.94 | 2019-2024 | Xarelto |
| Abiomed | $285.57 | 2023-2024 | Impella |
| Abbott Laboratories | $143.12 | 2022-2025 | Mitraclip |
| Glaxosmithkline, LLC. | $120.16 | 2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $113.24 | 2021 | |
| Pulmonx Corporation | $79.38 | 2024 | Chartis Catheter, Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter |
| Abbvie INC. | $63.20 | 2022-2024 | |
| Gilead Sciences, INC. | $33.85 | 2024 | |
| Phathom Pharmaceuticals, INC. | $28.89 | 2025 | Voquezna |
| Pfizer INC. | $27.40 | 2023 | |
| Lilly USA, LLC | $24.52 | 2023 | Mounjaro, Trulicity |
| Ironwood Pharmaceuticals, INC | $23.66 | 2024 | |
| Novo Nordisk INC | $23.25 | 2025 | Wegovy |
| Biohaven Pharmaceutical Holding Company LTD. | $21.12 | 2022 | |
| Dexcom, INC. | $15.26 | 2025 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andreh Carapiet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.